Determining the Safety of L-serine in ALS

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Amyotrophic Lateral Sclerosis (ALS)

In brief

The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Key facts

Study ID

NCT01835782

Run by

Phoenix Neurological Associates, LTD

People needed

20

Starts

2013-01-01

Last updated by the study team

2015-07-30

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-85
• Male or Female
• Clinically diagnosed with probable or definite ALS based on El Escorial criteria
• ALSFRS-R > 25
• Able to provide informed consent to and comply with all medical procedures

You may not qualify if…

• Outside age range of 18-85
• Subjects with forced vital capacity (FVC) below 60%
• Evidence of any motor neuron disease for over 3 years

Where it is running

• Phoenix Neurological Associates — Phoenix, Arizona, United States
• Forbes Norris MDA/ALS Research Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.